Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial

NCT04023331 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.

NCT NCT04023331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04023331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
Lead sponsor
Clarity Pharmaceuticals Ltd
Phase
Phase 1/2
Overall status
Terminated
Start date
August 18, 2020
Completion date
March 25, 2025
Enrollment
21 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, refractory neuroblastoma, relapsed neuroblastoma